GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer

Background: Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD i...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-07, Vol.40 (7), p.3939-3945
Main Authors: SELLE, FRÉDÉRIC, HEUDEL, PIERRE-ETIENNE, HARDY-BESSARD, ANNE-CLAIRE, POZET, ASTRID, MEUNIER, JEROME, GLADIEFF, LAURENCE, LOTZ, JEAN-PIERRE, PROVANSAL, MAGALI, AUGEREAU, PAULE, BERTON, DOMINIQUE, BONICHON-LAMICHHANE, NATHALIE, ORFEUVRE, HUBERT, PAUTIER, PATRICIA, KALBACHER, ELSA, TAZI, YOUSEF, SPAETH, DOMINIQUE
Format: Article
Language:English
Subjects:
Cancer
Doxorubicin
Hematology
Ovarian cancer
Patients
Platinum
Subgroups
Toxicity
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice. Patients and Methods: Patients with ROC after at least one platinum-based regimen received 1.1 mg/m2 trabectedin plus 30 mg/m2 PLD every 3 weeks. Efficacy and safety were evaluated in subgroups according to platinum-free interval [6-12 versus ≥12 months (partially or fully platinum sensitive, respectively)]. Results: Recurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups. Conclusion: Trabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14385